ロード中...
Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life
Today, monoclonal immunoglobulin gamma (IgG) antibodies have become a major option in cancer therapy especially for the patients with advanced or metastatic cancers. Efficacy of monoclonal antibodies (mAbs) is achieved through both its antigen-binding fragment (Fab) and crystallizable fragment (Fc)....
保存先:
| 出版年: | Front Immunol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5149539/ https://ncbi.nlm.nih.gov/pubmed/28018347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2016.00580 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|